GlassScriptPhysician profile
Ritu Gupta
NPI 1922344399
$4,989.72
in general payments reported to CMS, 2019-2025
25 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $530 · 2023: $719 · 2024: $1,534 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,767 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.73 |
| Education | $260.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $694.10 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $628.49 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $560.20 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $431.83 | 2021-2025 | |
| Amgen INC. | $409.22 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $373.92 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $351.67 | 2023-2025 | Winlevi |
| Regeneron Healthcare Solutions, INC. | $287.47 | 2024-2025 | Dupixent |
| Abbvie INC. | $275.11 | 2022-2025 | |
| Incyte Corporation | $173.24 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.00 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $144.69 | 2024 | Zoryve |
| Dermavant Sciences, INC. | $107.51 | 2024 | Vtama |
| Pfizer INC. | $92.81 | 2021-2025 | |
| Galderma Laboratories, L.P. | $68.13 | 2024-2025 | Nemluvio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Epi Health, LLC | $40.00 | 2022 | |
| Celgene Corporation | $30.57 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $28.41 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.84 | 2024 | Ycanth |
| Organon LLC | $16.17 | 2025 | |
| Janssen Biotech, INC. | $15.72 | 2023 | Simponi Aria, Stelara, Remicade |
| Medimetriks Pharmaceuticals, INC. | $15.66 | 2025 | |
| Dermira, INC. | $12.51 | 2021 | |
| Mission Pharmacal Company | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.